Brand-name drugmaker tactic ‘product hopping’ costs US healthcare system $4.7 billion annually, study says

The research study– launched Sept. 1 from the Washington, D.C.-based financial policy consulting firm and commissioned by the Coalition for Affordable Prescription Drugs– studied the effects of product hopping on the U.S. health care system..

Maia Anderson –
Tuesday, September 15th, 2020
Print|Email.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

Product hopping takes place when a brand-name drugmaker relocations patients to a reformulated variation of a drug when an existing drugs patent is set to end..

Discover the complete research study here.

An anti-competitive technique utilized by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion yearly, according to a research study from Matrix Global Advisors..

More short articles on pharmacy: Gilead expands oncology portfolio, gets Immunomedics for $21B8 considerations to take when getting ready for COVID-19 vaccine circulation Were not finished with remdesivir: Gilead CEO says trials underway for breathed in variation, outpatient IV variation.

Brand-name drugmakers use item hopping to preserve monopolies and avoid generic competition, the research study stated. Generic drug savings cant be recognized if patients have been relocated to a drug that is secured by patents before generic rivals can go into the marketplace..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

Just 5 circumstances of product hopping cost the U.S. health care system $4.7 billion every year, the research study discovered. It looked at circumstances of item hopping for the brand-name drugs Prilosec, TriCor, Suboxone, Doryx and Namenda..